| 尼妥珠单抗联合同步放、化疗治疗中晚期食管癌的近期疗效观察 |
| |
| 引用本文： | 刘慧娟1,车 宇1,刘 佳2. 尼妥珠单抗联合同步放、化疗治疗中晚期食管癌的近期疗效观察[J]. 现代肿瘤医学, 2015, 0(18): 2587-2590. DOI: 10.3969/j.issn.1672-4992.2015.18.10 |
| |
| 作者姓名： | 刘慧娟1 车 宇1 刘 佳2 |
| |
| 作者单位： | 1.陕西省肿瘤医院放疗科；2.胸外科，陕西 西安 710061 |
| |
| 摘 要： | 目的:观察尼妥珠单抗联合同步三维适形放疗、化疗治疗中晚期食管癌的近期疗效及不良反应。方法:46例中晚期食管癌采用尼妥珠单抗联合放、化疗与同数量单纯放、化疗组对比，观察治疗不良反应并评价近期疗效。结果:联合治疗组完全缓解率、有效率分别为47.8%、87.0%，较对照组的43.5%、84.8%有提高。急性不良反应发生率未见显著升高，与应用尼妥珠单抗产生的相关不良反应发生率较低。结论:尼妥珠单抗联合同步三维适形放、化疗治疗中晚期食管癌近期疗效较好，不良反应未见明显增加。
|
| 关 键 词： | 尼妥珠单抗 中晚期食管癌 疗效及毒副反应 |
Short term efficacy of Nimotuzumab with concurrent radiotherapy and chemotherapy for advanced esophageal cancer |
| |
| Liu Huijuan1,Che Yu1,Liu Jia2. Short term efficacy of Nimotuzumab with concurrent radiotherapy and chemotherapy for advanced esophageal cancer[J]. Journal of Modern Oncology, 2015, 0(18): 2587-2590. DOI: 10.3969/j.issn.1672-4992.2015.18.10 |
| |
| Authors: | Liu Huijuan1 Che Yu1 Liu Jia2 |
| |
| Affiliation: | 1.Department of Radiation Oncology;2.Department of Thoracic Surgery,Tumor Hospital of Shaanxi Province,Shaanxi Xi'an 710061,China. |
| |
| Abstract: | Objective:To investigate the efficacy and toxicity of Nimotuzumab combined with concurrent radiotherapy and chemotherapy in treatment of advanced esophageal cancer.Methods:All 46 cases of advanced esophageal cancer using Nimotuzumab combined radiotherapy and chemotherapy were compared with the same number of radiotherapy and chemotherapy group.Results:The complete remission and total response rate of combined group was 47.8% and 87.0%,higher than the control group's 43.5% and 84.8%.No significant increase in actue adverse reactions,Nimotuzumab showed a low incidence of side effects.Conclusion:The treatment of combined Nimotuzumab with radiotherapy and chemotherapy for advanced esophageal has a better curative effect and no significant increase in toxicity. |
| |
| Keywords: | Nimotuzumab esophageal cancer effect and toxicity |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
